Explore the most recent data on the drug situation in Europe provided by the EU Member States. These datasets underpin the analysis presented in the agency's work. Most data may be viewed interactively on screen and downloaded in Excel format.
We work closely with the 27 EU Member States plus Norway and Türkiye, candidates and potential candidates to the EU, the European Neighbourhood Policy countries and other third countries.
We have developed a systemic approach that brings together the human networks, processes and scientific tools necessary for collecting, analysing and reporting on the many aspects of the European drugs phenomenon.
How Weight Loss Drugs Like Ozempic Offer Benefits Beyond The Scale Weight Loss Tablets Doctors Prescribe
Location
Lisbon
Publication date
Reference
News release
In United States Publish Post Time: 2025-08-21
Weight loss medications like Ozempic and Wegovy are examples of GLP-1
receptor agonist drugs. By mimicking a hormone produced in the body, this
class of drugs has proven to be an effective way to treat diabetes and, more
recently, obesity. This year, clinical trials revealed their beneficial effects on
other chronic conditions that can be associated with obesity like heart failure
and kidney disease. Despite their widespread and growing use, GLP-1
receptor agonist drugs were by no means an overnight success – decades of
developments, unexpected discoveries, and some notable failures all paved
the way to the 2023 Breakthrough of the Year.
Read more about the Breakthrough of the Year:
How Weight Loss Drugs Like Ozempic Offer Benefits Beyond The Scale For Country: United States. City: Burbank, Columbus, Corona, Oklahoma City, Topeka
To schedule interviews, obtain informed comment, request written contributions or receive the latest news on the agency, please contact our media relations sector:
Kathy Robertson
Principal manager
Media relations and corporate communication